NAMS MENOPAUSE CERTIFICATION ACTUAL EXAM - (100
QUESTIONS) UP-TO-DATE ACTUAL EXAM QUESTIONS AND 100%
ACCURATE SOLUTIONS | VERIFIED ANSWERS - INSTANT PDF
DOWNLOAD
Examiner/Administrator: The North American Menopause Society
Candidate Name: ____________________________
Candidate ID: ________________________________
Date: ______________________________________
Examination Centre: _________________________
Time Allowed: 3 Hours
Total Questions: 100
Instructions to Candidates:
This assessment evaluates advanced clinical knowledge in menopause
management, emphasizing evidence-based decision-making, patient-centered
care, and risk-benefit analysis of therapeutic interventions. Answer all
questions by selecting the single best option. Clinical scenarios require
integration of physiology, pharmacology, and current practice guidelines. No
external materials are permitted. Carefully read each question and consider
all options before selecting your answer.
Core Competency Areas:
• Endocrinology of menopause
• Hormone therapy (HT) principles
• Non-hormonal treatment strategies
• Cardiovascular and metabolic implications
• Bone health and osteoporosis management
• Genitourinary syndrome of menopause (GSM)
• Cancer risk and screening considerations
• Psychosocial and cognitive aspects
, This simulated examination is designed to reflect the rigor and structure of
professional menopause certification assessments. It is an original
educational resource and does not contain actual exam items.
Q1. A 52-year-old woman presents with severe vasomotor symptoms 1 year
after menopause. She has no significant medical history and an intact uterus.
What is the most appropriate initial hormone therapy regimen?
A. Estrogen-only therapy
B. Combined estrogen-progestogen therapy
C. Progesterone-only therapy
D. Testosterone therapy
Correct Answer: B. Combined estrogen-progestogen therapy
Explanation: Women with an intact uterus require progestogen with
estrogen to prevent endometrial hyperplasia. A is incorrect due to risk of
endometrial cancer. C does not treat vasomotor symptoms effectively. D is not
first-line therapy for menopause symptoms.
Q2. A 60-year-old woman, 12 years postmenopause, requests initiation of
systemic hormone therapy for hot flashes. What is the primary concern?
A. Increased risk of osteoporosis
B. Increased cardiovascular risk
C. Improved lipid profile
D. Reduced breast cancer risk
Correct Answer: B. Increased cardiovascular risk
Explanation: Initiating HT >10 years after menopause increases
cardiovascular risk. A is incorrect as HT reduces osteoporosis risk. C is
,beneficial but outweighed by risks. D is incorrect; breast cancer risk may
increase.
Q3. Which mechanism primarily explains vasomotor symptoms during
menopause?
A. Increased estrogen levels
B. Hypothalamic thermoregulatory instability
C. Elevated progesterone
D. Increased cortisol production
Correct Answer: B. Hypothalamic thermoregulatory instability
Explanation: Declining estrogen affects hypothalamic temperature control.
A is incorrect since estrogen decreases. C and D are not primary mechanisms.
Q4. A woman with a history of breast cancer seeks treatment for hot flashes.
What is the safest first-line option?
A. Systemic estrogen
B. Combined HT
C. SSRIs or SNRIs
D. Testosterone
Correct Answer: C. SSRIs or SNRIs
Explanation: Non-hormonal options are preferred in breast cancer
survivors. A and B are contraindicated. D is not appropriate.
Q5. Which hormone change is most characteristic of menopause?
A. Increased estrogen
, B. Decreased FSH
C. Increased FSH
D. Increased progesterone
Correct Answer: C. Increased FSH
Explanation: Ovarian failure leads to decreased estrogen and increased
FSH. A, B, and D are incorrect trends.
Q6. A patient using transdermal estrogen has which advantage over oral
estrogen?
A. Increased liver metabolism
B. Lower risk of thromboembolism
C. Higher triglyceride levels
D. Reduced efficacy
Correct Answer: B. Lower risk of thromboembolism
Explanation: Transdermal estrogen bypasses hepatic first-pass metabolism,
reducing clot risk. A and C are incorrect. D is false.
Q7. Which condition is an absolute contraindication to systemic hormone
therapy?
A. Controlled hypertension
B. Migraine without aura
C. Active liver disease
D. Mild hyperlipidemia
Correct Answer: C. Active liver disease
QUESTIONS) UP-TO-DATE ACTUAL EXAM QUESTIONS AND 100%
ACCURATE SOLUTIONS | VERIFIED ANSWERS - INSTANT PDF
DOWNLOAD
Examiner/Administrator: The North American Menopause Society
Candidate Name: ____________________________
Candidate ID: ________________________________
Date: ______________________________________
Examination Centre: _________________________
Time Allowed: 3 Hours
Total Questions: 100
Instructions to Candidates:
This assessment evaluates advanced clinical knowledge in menopause
management, emphasizing evidence-based decision-making, patient-centered
care, and risk-benefit analysis of therapeutic interventions. Answer all
questions by selecting the single best option. Clinical scenarios require
integration of physiology, pharmacology, and current practice guidelines. No
external materials are permitted. Carefully read each question and consider
all options before selecting your answer.
Core Competency Areas:
• Endocrinology of menopause
• Hormone therapy (HT) principles
• Non-hormonal treatment strategies
• Cardiovascular and metabolic implications
• Bone health and osteoporosis management
• Genitourinary syndrome of menopause (GSM)
• Cancer risk and screening considerations
• Psychosocial and cognitive aspects
, This simulated examination is designed to reflect the rigor and structure of
professional menopause certification assessments. It is an original
educational resource and does not contain actual exam items.
Q1. A 52-year-old woman presents with severe vasomotor symptoms 1 year
after menopause. She has no significant medical history and an intact uterus.
What is the most appropriate initial hormone therapy regimen?
A. Estrogen-only therapy
B. Combined estrogen-progestogen therapy
C. Progesterone-only therapy
D. Testosterone therapy
Correct Answer: B. Combined estrogen-progestogen therapy
Explanation: Women with an intact uterus require progestogen with
estrogen to prevent endometrial hyperplasia. A is incorrect due to risk of
endometrial cancer. C does not treat vasomotor symptoms effectively. D is not
first-line therapy for menopause symptoms.
Q2. A 60-year-old woman, 12 years postmenopause, requests initiation of
systemic hormone therapy for hot flashes. What is the primary concern?
A. Increased risk of osteoporosis
B. Increased cardiovascular risk
C. Improved lipid profile
D. Reduced breast cancer risk
Correct Answer: B. Increased cardiovascular risk
Explanation: Initiating HT >10 years after menopause increases
cardiovascular risk. A is incorrect as HT reduces osteoporosis risk. C is
,beneficial but outweighed by risks. D is incorrect; breast cancer risk may
increase.
Q3. Which mechanism primarily explains vasomotor symptoms during
menopause?
A. Increased estrogen levels
B. Hypothalamic thermoregulatory instability
C. Elevated progesterone
D. Increased cortisol production
Correct Answer: B. Hypothalamic thermoregulatory instability
Explanation: Declining estrogen affects hypothalamic temperature control.
A is incorrect since estrogen decreases. C and D are not primary mechanisms.
Q4. A woman with a history of breast cancer seeks treatment for hot flashes.
What is the safest first-line option?
A. Systemic estrogen
B. Combined HT
C. SSRIs or SNRIs
D. Testosterone
Correct Answer: C. SSRIs or SNRIs
Explanation: Non-hormonal options are preferred in breast cancer
survivors. A and B are contraindicated. D is not appropriate.
Q5. Which hormone change is most characteristic of menopause?
A. Increased estrogen
, B. Decreased FSH
C. Increased FSH
D. Increased progesterone
Correct Answer: C. Increased FSH
Explanation: Ovarian failure leads to decreased estrogen and increased
FSH. A, B, and D are incorrect trends.
Q6. A patient using transdermal estrogen has which advantage over oral
estrogen?
A. Increased liver metabolism
B. Lower risk of thromboembolism
C. Higher triglyceride levels
D. Reduced efficacy
Correct Answer: B. Lower risk of thromboembolism
Explanation: Transdermal estrogen bypasses hepatic first-pass metabolism,
reducing clot risk. A and C are incorrect. D is false.
Q7. Which condition is an absolute contraindication to systemic hormone
therapy?
A. Controlled hypertension
B. Migraine without aura
C. Active liver disease
D. Mild hyperlipidemia
Correct Answer: C. Active liver disease
